|
GB9619757D0
(en)
*
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
|
JP2000080047A
(ja)
*
|
1998-06-30 |
2000-03-21 |
Takeda Chem Ind Ltd |
医 薬
|
|
EP1093370B1
(en)
*
|
1998-06-30 |
2006-02-22 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical composition for the treatment of diabetes
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
DZ2937A1
(fr)
*
|
1998-11-12 |
2004-03-15 |
Smithkline Beecham Plc |
Compositions nouvelles de sensibilidants à l'insuline.
|
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
|
WO2000028989A1
(en)
*
|
1998-11-12 |
2000-05-25 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
|
US6696495B2
(en)
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
|
US6723717B1
(en)
|
1999-06-01 |
2004-04-20 |
The University Of Texas Southwestern Medical Center |
Sulfur-containing thyroxane derivatives and their use as hair growth promotors
|
|
US6680344B1
(en)
|
1999-06-01 |
2004-01-20 |
The University Of Texas Southwestern Medical Center |
Method of treating hair loss using diphenylmethane derivatives
|
|
MXPA01012494A
(es)
|
1999-06-01 |
2002-07-02 |
Univ Texas Southwestern Med Ct |
Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
|
|
GB9914744D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Knoll Ag |
Therapeutic agents
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
WO2002083631A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
PL376577A1
(pl)
|
2002-06-17 |
2006-01-09 |
Themis Laboratories Private Limited |
Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
|
|
MXPA05003355A
(es)
*
|
2002-10-05 |
2005-10-18 |
Hanmi Pharm Ind Co Ltd |
Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.
|
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
|
AR045330A1
(es)
*
|
2003-08-07 |
2005-10-26 |
Sb Pharmco Inc |
Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
|
|
GB0318824D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Glaxo Group Ltd |
Novel composition
|
|
TWI339586B
(en)
*
|
2003-10-31 |
2011-04-01 |
Takeda Chemical Industries Ltd |
Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
|
|
KR100627687B1
(ko)
*
|
2005-04-20 |
2006-09-25 |
주식회사 씨티씨바이오 |
시부트라민 유리염기 함유 조성물 및 이의 제조방법
|
|
KR101294014B1
(ko)
|
2006-01-06 |
2013-08-09 |
선오비온 파마슈티컬스 인코포레이티드 |
모노아민 재흡수 저해제로서의 시클로알킬아민
|
|
MX2009002781A
(es)
|
2006-09-15 |
2009-03-30 |
Reviva Pharmaceuticals Inc |
Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
|
|
KR100812538B1
(ko)
*
|
2006-10-23 |
2008-03-11 |
한올제약주식회사 |
약물 제어방출형 메트포르민-글리메피리드 복합제제
|
|
BRPI0716002A2
(pt)
*
|
2006-11-22 |
2013-07-30 |
Sk Chemicals Co Ltd |
complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
|
|
US8889632B2
(en)
|
2007-01-31 |
2014-11-18 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
|
EP2508531B1
(en)
|
2007-03-28 |
2016-10-19 |
President and Fellows of Harvard College |
Stitched polypeptides
|
|
WO2011003039A2
(en)
|
2009-07-02 |
2011-01-06 |
Dexcom, Inc. |
Analyte sensors and methods of manufacturing same
|
|
WO2012003501A2
(en)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
|
SI2603600T1
(sl)
|
2010-08-13 |
2019-04-30 |
Aileron Therapeutics, Inc. |
Peptidomimetični makrocikli
|
|
TW201806968A
(zh)
|
2011-10-18 |
2018-03-01 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
IN2014MN01407A
(cg-RX-API-DMAC10.html)
|
2011-12-30 |
2015-07-03 |
Reviva Pharmaceuticals Inc |
|
|
KR102112373B1
(ko)
|
2012-02-15 |
2020-05-18 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티드모방체 마크로사이클
|
|
HK1205454A1
(en)
|
2012-02-15 |
2015-12-18 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
WO2014071241A1
(en)
|
2012-11-01 |
2014-05-08 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
BR112017005598A2
(pt)
|
2014-09-24 |
2017-12-12 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos e usos dos mesmos
|
|
WO2016154058A1
(en)
|
2015-03-20 |
2016-09-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|